A Bone-Strengthening Pill (BSP) as a dietary supplement to improve blood circulation and strengthen bone and muscle is characterized in that it is made from the following raw materials: Angelica Sinensis, Pseudo-ginseng and Carthamus Tinctorius L. BSP has the following beneficial effects: promoting blood circulation, dredging microcirculatory disturbance, significantly improving the level of human health, improving blood running in bone tissue and muscle tissue, and preventing or repairing microscopic damage of bone, cartilage tissue and muscle tissue.

Disclosed herein is a pharmaceutical composition for preventing, alleviating or treating neurodegenerative diseases. The pharmaceutical composition contains, as active ingredients, Curcumae longae rhizome, Gastrodiae rhizoma, Polygalae radix, Salviae radix, Chaenomeles fructus, Paeoniae radix, Glycyrrhizae radix, Atractylodis rhizome, and Pulvis aconiti tuberis purificatum. The pharmaceutical composition is prepared by a method including the steps of: mixing Curcumae longae rhizome, Gastrodiae rhizoma, Polygalae radix, Salviae radix, Chaenomeles fructus, Paeoniae radix, Glycyrrhizae radix, Atractylodis rhizome, and Pulvis aconiti tuberis purificatum to obtain a mixture, and extracting the mixture to obtain a mixture extract; filtering the mixture extract; concentrating the mixture extract; and drying the mixture extract.

Disclosed herein is a pharmaceutical composition for preventing, alleviating or treating neurodegenerative diseases. The pharmaceutical composition contains, as active ingredients, Curcumae longae rhizome, Gastrodiae rhizoma, Polygalae radix, Salviae radix, Chaenomeles fructus, Paeoniae radix, Glycyrrhizae radix, Atractylodis rhizome, and Pulvis aconiti tuberis purificatum. The pharmaceutical composition is prepared by a method including the steps of: mixing Curcumae longae rhizome, Gastrodiae rhizoma, Polygalae radix, Salviae radix, Chaenomeles fructus, Paeoniae radix, Glycyrrhizae radix, Atractylodis rhizome, and Pulvis aconiti tuberis purificatum to obtain a mixture, and extracting the mixture to obtain a mixture extract; filtering the mixture extract; concentrating the mixture extract; and drying the mixture extract.

A traditional Chinese medicine composition, and preparation method, and application thereof. The traditional Chinese medicine composition includes the following raw medicines in parts by weight: 10-35 parts of root of Chinese thorowax, 5-25 parts of immature bitter orange, 3-20 parts of fresh root and rhizome of sorrel rhubarb, 3-20 parts of root of baikal skullcap, 3-20 parts of white peony root, 3-15 parts of dried ginger, 5-20 parts of leech, 3-20 parts of root of ural licorice, 3-20 parts of root pilose asiabell, 3-20 parts of rhizome of largehead atractylodes, and 3-25 parts of tuber of pinellia. The traditional Chinese medicine composition has excellent effects in lowering blood lipids and cholesterol levels, particularly in lowering blood triglyceride. The traditional Chinese medicine composition also has excellent effects in slowing formation of atherosclerotic plaques, clearing the atherosclerotic plaques, and preventing and treating atherosclerosis.

A traditional Chinese medicine composition, and preparation method, and application thereof. The traditional Chinese medicine composition includes the following raw medicines in parts by weight: 10-35 parts of root of Chinese thorowax, 5-25 parts of immature bitter orange, 3-20 parts of fresh root and rhizome of sorrel rhubarb, 3-20 parts of root of baikal skullcap, 3-20 parts of white peony root, 3-15 parts of dried ginger, 5-20 parts of leech, 3-20 parts of root of ural licorice, 3-20 parts of root pilose asiabell, 3-20 parts of rhizome of largehead atractylodes, and 3-25 parts of tuber of pinellia. The traditional Chinese medicine composition has excellent effects in lowering blood lipids and cholesterol levels, particularly in lowering blood triglyceride. The traditional Chinese medicine composition also has excellent effects in slowing formation of atherosclerotic plaques, clearing the atherosclerotic plaques, and preventing and treating atherosclerosis.

Described herein are cannabinoid therapy formulations for sleep, pain, and anxiety conditions. Also provided are methods for improving sleep quality, relieving pain and/or improving anxiety symptoms.

Described herein are cannabinoid therapy formulations for sleep, pain, and anxiety conditions. Also provided are methods for improving sleep quality, relieving pain and/or improving anxiety symptoms.

Described herein are cannabinoid therapy formulations for sleep, pain, and anxiety conditions. Also provided are methods for improving sleep quality, relieving pain and/or improving anxiety symptoms.

Provided in the present invention is a pharmaceutically active ingredient extract extracted from Polygala japonica Houtt., which extract comprises a flavonol compound of the following formula (I) structure as a first active ingredient, and optionally comprises a xanthone compound selected from the following formula (II) as a second active ingredient and a glycolipid compound selected from the following formula (III-1) as a third active ingredient. An animal experiment confirms that the drug of the present invention has significantly better effects than potassium sodium hydrogen citrate in typical test indicators such as calcium oxalate crystal aggregation, renal interstitial inflammatory cell infiltration and renal tubule dilation lesions, showing that the drug has high potential and market prospects in the treatment of urolithiasis and urinary tract infections or kidney damage caused by urolithiasis, and as an adjuvant drug after surgical treatment of urolithiasis.

##STR00001##

Provided in the present invention is a pharmaceutically active ingredient extract extracted from Polygala japonica Houtt., which extract comprises a flavonol compound of the following formula (I) structure as a first active ingredient, and optionally comprises a xanthone compound selected from the following formula (II) as a second active ingredient and a glycolipid compound selected from the following formula (III-1) as a third active ingredient. An animal experiment confirms that the drug of the present invention has significantly better effects than potassium sodium hydrogen citrate in typical test indicators such as calcium oxalate crystal aggregation, renal interstitial inflammatory cell infiltration and renal tubule dilation lesions, showing that the drug has high potential and market prospects in the treatment of urolithiasis and urinary tract infections or kidney damage caused by urolithiasis, and as an adjuvant drug after surgical treatment of urolithiasis.

##STR00001##